Lakewood-Amedex Biotherapeutics, Inc.
LABT
$2.30
-$0.02-0.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 367.09% | 33.93% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 327.35% | 24.53% | |||
| Operating Income | -327.35% | -24.53% | |||
| Income Before Tax | -308.53% | -23.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -308.53% | -23.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -308.53% | -23.95% | |||
| EBIT | -327.35% | -24.53% | |||
| EBITDA | -327.79% | -24.57% | |||
| EPS Basic | -35.59% | 48.40% | |||
| Normalized Basic EPS | -101.30% | -23.95% | |||
| EPS Diluted | -35.59% | 48.40% | |||
| Normalized Diluted EPS | -101.30% | -23.95% | |||
| Average Basic Shares Outstanding | 102.97% | -0.01% | |||
| Average Diluted Shares Outstanding | 102.97% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||